Target
ICANS
1 abstract
Abstract
Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6.Org: Lehigh Valley Health Network, University of Oklahoma, Stephenson Cancer Center, H. Lee Moffitt Cancer Center at Memorial Healthcare System, Stony Brook University Medical Center,